I have been very fortunate – its been nearly three years since my diagnosis and I am NED (no evidence of disease, or the solid tumor equivalent of remission which is more commonly used for liquid […]
A novel PALB2 truncating mutation in an Italian family with male breast cancer Vietri MT, Caliendo G, Casamassimi A, Cioffi M, De Paola ML, Napoli C, Molinari AM Oncol Rep. 2015 Mar;33(3):1243-7. doi: 10.3892/or.2014.3685. Epub […]
Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB Hered Cancer Clin Pract. […]
Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations S Deb, S Q Wong1, J Li, H Do, J Weiss, D Byrne, A Chakrabarti, T […]
Earlier this week I blogged about the cancer conference, the WIN Symposium which I attended last week. I summarized some of the current challenges in developing personalized cancer therapies, including the complexity of cancer. The […]
Last week I attended a great cancer conference, the WIN Symposium which this year was titled “Personalized Cancer Therapy – from Innovation to Implementation”. This conference has brought together some of the best thinkers and […]
This Wednesday was only my fourth taxol, but I am beginning to feel the side effects. It’s a little earlier than anticipated, and its nothing major. And of course, everyone’s experience is a little different. Mostly I have the feeling of cold feet…
You read a lot about personalized cancer therapy both in scientific journals and in the general press. The idea is that in the (near) future doctors will be able to learn a lot more information about your tumor, and pick just the right therapy to …
